BachemKPI data tables
Bachem operating metrics behind the KPI charts, newest period first (up to 24 periods per chart). Periods use each company's own fiscal labels where the source does; each table names its source.
| Period | Capacity expansion | (residual) |
|---|---|---|
| FY 2025 | 295 | 37.6 |
Source: Bachem FY 2025 results: capex CHF 332.6 million, of which CHF 295 million capacity expansion (48% of sales). https://www.bachem.com/news-events/financial-reports/.
| Period | Net sales |
|---|---|
| FY 2025 | 695.1 |
Source: Bachem FY 2025 results: net sales CHF 695.1 million, up 14.8%. https://www.bachem.com/news-events/financial-reports/.
| Period | GLP-1 (top customer, implied NVO, est.) | GLP-1 (other sponsors, est.) | Other peptide CDMO + commercial | Generics + research peptides |
|---|---|---|---|---|
| 2024 | 320 | 130 | 100 | 55 |
| 2023 | 290 | 110 | 120 | 58 |
| 2022 | 230 | 80 | 165 | 57 |
| 2021 | 180 | 60 | 190 | 73 |
| 2020 | 120 | 40 | 170 | 72 |
Source: Bachem annual + half-year reports (Geschaeftsbericht; SIX Swiss Exchange + bachem.com investor relations); Bachem ad-hoc disclosures on sales + capacity expansion. Reported Group sales: 2020 CHF 402.0M, 2021 CHF 503.2M, 2022 CHF 531.7M, 2023 CHF 577.8M, 2024 CHF 605.3M; the per-year column totals match these. Bachem discloses customer-concentration ranges (e.g. top-3 share) but not customer names or a GLP-1-vs-other revenue split, so the per-customer breakdown shown here is estimate-driven from company commentary plus analyst attribution.
| Period | Bubendorf CH (legacy HQ + SPPS) | Vista CA (US) | Torrance CA (US) | Other sites + research scale |
|---|---|---|---|---|
| 2027 | 300 | 130 | 90 | 20 |
| 2026 | 270 | 110 | 60 | 18 |
| 2025 | 230 | 85 | 30 | 16 |
| 2024 | 180 | 55 | 10 | 14 |
| 2023 | 130 | 35 | 0 | 12 |
| 2022 | 100 | 20 | 0 | 10 |
Source: Bachem annual reports (Geschäftsbericht German + English; available via SIX Swiss Exchange + bachem.com investor relations); Bachem Capital Markets Day decks (2024 + 2025); Bachem ad-hoc disclosures on capex announcements per site (Bubendorf 2022-2024 tranches, Vista 2023-2025 tranches, Torrance 2024-2025 tranches); cross-reference with Bachem half-year reports + media coverage of plant expansions. Capacity is indexed because Bachem does not disclose absolute reactor counts or absolute production volumes per site for competitive reasons; the index reflects the relative scale-up trajectory.